Survodutide news and clinical trials

Researchers published a letter in Diabetes, obesity & metabolism regarding the interpretation of survodutide renoprotection in a hyperfiltration model.

Researchers developed HyM 2 Surv, a hypergraph-based framework for survival prediction that integrates pathological images and microbiome data. This model outperformed state-of-the-art methods by an average of 6.10% in C-index across four TCGA datasets.

A letter published in Diabetes, obesity & metabolism explores whether survodutide provides renoprotection beyond its known metabolic and haemodynamic effects in patients with diabetic kidney disease.

Boehringer Ingelheim registered a phase 3 trial to evaluate initiation strategies for survodutide, including new use or switching from semaglutide or tirzepatide, in 350 adults with obesity but no diabetes. The study aims to determine if survodutide helps these participants lose weight.

A phase 3 trial published in The New England journal of medicine showed that weekly survodutide doses of 3.6 mg or 6.0 mg resulted in significant weight reduction in adults with obesity and type 2 diabetes. Mean weight change at week 76 was -8.2% and -9.8% respectively, versus -3.9% for placebo.

A study in Contemporary clinical trials reviewed the mechanistic rationale and clinical evidence for survodutide. In a phase 2 trial, participants without diabetes receiving a 4.8-mg dose achieved a mean body-weight reduction of 18.7% at 46 weeks, compared to 2.3% for placebo.

A study in Diabetes, obesity & metabolism found that survodutide improved metabolic and renal outcomes in a mouse model of advanced diabetic kidney disease. The treatment significantly reduced body weight and hyperglycemia while mitigating kidney hypertrophy and glomerulosclerosis.

Boehringer Ingelheim registered a phase 3b trial to evaluate the safety and efficacy of survodutide for weight loss in 600 peri- and post-menopausal women with overweight or obesity.

Boehringer Ingelheim registered a phase 3b trial to test if survodutide affects heart structure and function in 600 participants with obesity and metabolic dysfunction-associated steatotic liver disease.

Groupe Hospitalier Pitie-Salpetriere completed a retrospective observational cohort study of 95015 participants to evaluate if COVID-19 vaccination near the initiation of immune checkpoint inhibitor therapy is associated with survival in adults with cancer.

A corrigendum was published regarding a 2025 review of prognostic factors for age-related macular degeneration.

Nature medicine published an erratum regarding a phase 3 trial of survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease.

Boehringer Ingelheim registered a phase 1 trial of 44 participants to establish the bioequivalence of survodutide administered via a pre-filled syringe compared to a vial in healthy, overweight, or obese participants.

A study in Diabetes therapy describes the design and baseline characteristics of the SYNCHRONIZE-CN phase 3 trial, which evaluates survodutide in 306 Chinese adults with overweight or obesity. The trial aims to measure percentage weight change and 5% weight reduction through week 52.

Boehringer Ingelheim registered a phase 3 trial to evaluate the efficacy and safety of survodutide for blood sugar control in 600 participants with type 2 diabetes.

A mediation analysis of a phase 2 trial in MASH patients indicated that while survodutide-induced weight reduction significantly impacted steatosis, inflammation and fibrosis improvements were largely independent of weight loss. This suggests direct glucagon receptor agonism may benefit the liver.

Boehringer Ingelheim completed a phase 1 trial of 100 participants comparing the bioavailability of two survodutide formulations administered subcutaneously via pre-filled syringe.

Groupe Hospitalier Pitie-Salpetriere registered a retrospective observational cohort study of 95015 participants to evaluate if COVID-19 vaccination near the initiation of immune checkpoint inhibitor therapy is associated with survival in adults with cancer.

Boehringer Ingelheim completed a phase 3 trial investigating the cardiovascular safety of survodutide in 5531 participants with overweight or obesity.

Researchers developed a framework called PANA-Surv to improve multi-omics cancer survival predictions using KEGG pathways. This method significantly outperformed existing models on 10 cancer cohorts and identified 18 prognostic genes in a breast cancer case study.

Researchers conducting phase 2 trials of survodutide found that the drug improved beta-cell function and insulin sensitivity in adults with type 2 diabetes or obesity. These metabolic benefits occurred largely independently of bodyweight changes.

Boehringer Ingelheim completed a phase 1 trial of 56 participants comparing two survodutide formulations delivered via a pre-filled syringe and a pen-like injector. The study investigated whether these different delivery methods result in similar body uptake.

In a phase 3 trial of 725 adults with obesity, researchers found that once-weekly survodutide treatment resulted in significantly greater weight loss than placebo at week 76. The mean body weight change was -12.2% in the 3.6-mg group and -13.0% in the 6.0-mg group compared to -5.4% for placebo.

A plain language review summarized the proposed mechanism of survodutide as a treatment for obesity and metabolic dysfunction-associated steatohepatitis. The paper discusses how the medication is currently being tested in clinical trials.

A phase 3 trial of 216 adults found that 6.0 mg of weekly survodutide was superior to placebo for reducing liver fat and body weight in patients with obesity and metabolic dysfunction-associated steatotic liver disease.

Researchers published the design of the SYNCHRONIZE-JP trial, which is evaluating the efficacy and safety of 3.6 mg or 6.0 mg weekly survodutide in Japanese adults with obesity. The trial will assess weight loss over 76 weeks.

The SURV-ICE cohort study assessed recruitment for a nationwide survey of cancer survivors and controls in Iceland. The study found that 5489 of 10,005 cancer survivors and 2297 of 5663 controls responded, demonstrating the feasibility of registry-based research without incentives.

Researchers published a study introducing Rek-Surv, a lightweight deep survival model using a Kolmogorov-Arnold Network architecture for predicting infectious disease onset. The model achieved a concordance index of 0.962 on a citrus Huanglongbing dataset while using only 114 trainable parameters.

Boehringer Ingelheim completed a phase 3 trial of 755 participants to determine if weekly subcutaneous survodutide helps adults living with overweight or obesity and type 2 diabetes mellitus to lose weight.

A review article described survodutide as a dual glucagon and GLP-1 receptor agonist. The review highlighted its potential to manage obesity and metabolic-associated fatty liver disease through appetite regulation and enhanced glucose metabolism.

Boehringer Ingelheim completed a phase 3 study of 726 participants comparing the efficacy of weekly subcutaneous survodutide versus placebo for weight loss in adults with overweight or obesity without type 2 diabetes. The treatment period lasted 76 weeks.

A clinical trial simulation for the SYNCHRONIZE phase 3 program allowed researchers to adjust study protocols based on feedback from site staff and participants. Recommendations led to changes in visit intervals and virtual visit options to improve engagement.

Boehringer Ingelheim completed a phase 1 trial of 56 participants to compare the uptake of two survodutide formulations when delivered via a pre-filled syringe versus a pre-filled pen.

Boehringer Ingelheim registered a phase 1 trial of 80 participants to assess the bioequivalence of two survodutide formulations after multiple-dose treatment in participants living with overweight or obesity.

Researchers found that survodutide accesses circumventricular organs in the brain and activates appetite-regulating neuronal regions. Data suggests its weight-loss effects are primarily GLP-1R dependent, supporting its dual mechanism of action for obesity and MASH.

Boehringer Ingelheim completed a phase 3 study involving 307 Chinese participants to test whether weekly subcutaneous survodutide injections help individuals with overweight or obesity lose weight. The trial compared survodutide against a placebo over approximately 19 months.

Boehringer Ingelheim completed a phase 1 trial of 34 participants assessing if different doses of survodutide affect the pharmacokinetics of bupropion, caffeine, and midazolam. The study examined blood concentration levels of these substances after weekly survodutide administration.

This letter outlines a blueprint for defining and operationalizing disease modification in obesity clinical trials, based on the SYNCHRONIZE-1 study of survodutide.

A study in mice found that hepatic GCGR is necessary for the metabolic effects and superior weight loss seen with a structural analogue of the dual GCGR/GLP-1R agonist survodutide.

Boehringer Ingelheim completed a phase 3 study with 274 Japanese participants evaluating the efficacy and safety of once-weekly subcutaneous survodutide versus placebo in patients with obesity disease. The trial assessed weight loss outcomes over approximately one and a half years.

Boehringer Ingelheim completed a phase 3 study of 218 participants examining the efficacy of weekly subcutaneous survodutide for reducing liver fat and body weight in individuals with obesity and nonalcoholic steatohepatitis. The trial lasted 48 weeks.

This study published baseline characteristics of participants enrolled in the SYNCHRONIZE cardiovascular outcomes trial for the obesity treatment survodutide.

Researchers published baseline data for the SYNCHRONIZE-2 phase 3 trial of survodutide, which involves 752 participants with obesity and type 2 diabetes. The cohort had a mean age of 55.7 years and a mean body mass index of 36.5 kg/m 2.

Researchers published baseline characteristics for the phase 3 SYNCHRONIZE-1 trial evaluating survodutide for obesity in 725 adults without type 2 diabetes. Participants had a mean age of 47.1 years and mean BMI of 37.9 kg/m 2.

Boehringer Ingelheim completed a phase 1 trial of 16 participants investigating the relative bioavailability of two survodutide formulations after subcutaneous administration. The study was an open-label, crossover trial comparing a reference formulation to a test formulation.

Boehringer Ingelheim registered a phase 1 trial of 100 participants to compare the bioavailability of two survodutide formulations administered subcutaneously via pre-filled syringe.